Lexicon Pharmaceuticals (NASDAQ:LXRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release. Analysts are ...

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Lexicon Pharmaceuticals, Inc. announced that it will release its financial results for the fourth quarter and full year 2024 on March 6, 2025, after market close. Following the release, the company's ...

Lexicon Pharmaceuticals (LXRX) is scheduled to report Q2 earnings on August 5, 2026. Analysts estimate EPS of $-0.05 and quarterly revenue of $4.34M. In the most recent quarter (Q1), Lexicon ...

Lexicon Pharmaceuticals (LXRX) has priced its public offering of 32M shares of its common stock, par value $0.001, at $1.30 per share to raise $41.6M. The firm has granted the underwriters a 30-day ...

Eli Lilly and Boehringer Ingelheim recently celebrated a heart failure FDA label expansion for their SGLT 2 drug, Jardiance, and now a potential rival from Lexicon Pharmaceuticals has suffered a ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its ...